Orphan medicines are licensed to diagnose, prevent, or treat rare conditions that are life-threatening or chronically debilitating. ‘Orphan’ status grants up to 10 years of market exclusivity from the date of first approval of the product for that indication. Orphan medicines with paediatric indications may be eligible for an additional two years of exclusivity, for a total of 12 years.
dfgdfgdf
vnbm vbnvbhn